The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry

被引：38

作者：

Agnelli G. ^{[1
,174
]}

Gitt A.K. ^{[2
]}

Bauersachs R. ^{[3
,4
,87
]}

Fronk E.-M. ^{[5
]}

Laeis P. ^{[5
]}

Mismetti P. ^{[6
]}

Monreal M. ^{[7
]}

Willich S.N. ^{[8
]}

Wolf W.-P. ^{[4
]}

Cohen A.T. ^{[9
]}

Brodmann M. ^{[10
]}

Rief P. ^{[10
]}

Eischer L. ^{[11
]}

Stoshikj S. ^{[11
]}

Hirschl M. ^{[12
]}

Weinmann S. ^{[12
]}

Marschang P. ^{[13
]}

Abbadie F. ^{[14
]}

Achkar A. ^{[15
]}

Addala A. ^{[16
]}

Adnet F. ^{[17
]}

Alexandra J.-F. ^{[18
]}

Aquilanti S. ^{[19
]}

Belhassane A. ^{[20
]}

Benaroya A. ^{[21
]}

Berremili T. ^{[22
]}

Grenot M.C. ^{[22
]}

Birr V. ^{[23
]}

Holtea D. ^{[23
]}

Bonnin C. ^{[24
]}

Bosler F. ^{[25
]}

Durand M.-G.B. ^{[26
]}

Brisot D. ^{[27
]}

Brousse C. ^{[28
]}

De La Fuente T. ^{[28
]}

Cayman R. ^{[29
]}

Cazaubon M. ^{[30
]}

Champion O. ^{[31
]}

Chanut M. ^{[32
]}

Chevalet P. ^{[33
]}

Connault J. ^{[34
]}

Durant C. ^{[34
]}

Constans J. ^{[35
]}

Cordeanu M. ^{[36
,81
]}

Couturaud F. ^{[37
]}

Lacut K. ^{[37
]}

De Dedker L. ^{[38
]}

Decoulx E. ^{[39
]}

Derrien B. ^{[40
]}

Diamand J.-M. ^{[41
]}

机构：

[1] Santa Maria della Misericordia Hospital, University of Perugia, Perugia

[2] Herzzentrum Ludwigshafen Med. Klinik B, Ludwigshafen

[3] University of Mainz, Klinikum Darmstadt GmbH, Darmstadt, Center of Thrombosis and Hemostasis, Mainz

[4] University of Mainz, Center of Thrombosis and Haemostasis, Mainz

[5] Daiichi Sankyo Europe GmbH, Munich

[6] CHU Saint-Etienne Hopital Nord, Saint Etienne

[7] Hospital Universitari Germans Trias i Pujol, Barcelona

[8] Charité - Universitätsmedizin Berlin, Berlin

[9] Guys and St Thomas' Hospitals NHS Foundation Trust, King's College, Westminster Bridge Road, London

[10] Universitätsklinikum Graz, Graz

[11] Medizinische Universität Wien, Wien

[12] Landesklinikum Zwettl, Zwettl

[13] Universitätsklinik Innsbruck für Innere Medizin, Innsbruck

[14] Centre hispitalier Jacques Lacarin, Vichy

[15] CHI Eure et Seine - Site de Vernon, Vernon

[16] Perrone Reynaldo, Lyon

[17] Hopital Avicenne, Bobigny

[18] Hopital Bichat Claude Bernard, Paris

[19] Espace ARTOIS Santé, Arras

[20] Centre Hospitalier de Cambrai, Cambrai Cedex

[21] Pole Sante Des Aspres, Thuir

[22] CH Annecy Genevois, Pringy Cedex

[23] CHU Emile Muller, Mulhouse Cedex

[24] Le Gibraltar 10-12, Nice

[25] 19 rue Robert Schumann, Sarrebourg

[26] Résid des remparts 7 rue des lombards, Hennebont

[27] Centre Commercial La Croisee, Clapier

[28] Clinique Du Parc, Castelnau-le-Lez

[29] 8 rue des des de l'aire, Bourgoin Jallieu

[30] 17 rue Mesnil, Paris

[31] 6 Avenue Georges Pompidou, Chalon-sur- Saône

[32] Immeuble Le Clos de Bellande, Aubenas

[33] Hopital Bellier, Nantes

[34] CHU Hôtel-Dieu de Nantes, Nantes

[35] Hopital St Andre, Bordeaux

[36] CHRU Strasbourg, Strasbourg

[37] CHRU Hopital Cavale Blanche, Brest

[38] François Xavier Piloquet, Hôpital Nord Laennec, Saint Herblain

[39] Centre Hospitalier de Tourcoing, Tourcoing

[40] Centre Hospitalier

[41] Centre De Medecine Vasculaire, Grenoble

[42] 25 Route De Creon, Langoiran

[43] Centre Hospitalier De Saint Quentin, St Quentin

[44] CHU Amiens Picardie - Hôpital Sud

[45] Hôpital Saint Antoine, Paris

[46] CHU Dijon Service De Medecine Interne, Dijon

[47] Hôpital Saint Charles, Toul

[48] Hôpital Pasteur, Nice

[49] 14 rue Maurice Devillers, Peronne

[50] Clinique Monie, Villefranche-de-Lauragais

来源：

Thrombosis Journal | / 13卷 / 1期

关键词：

Anticoagulation; Novel Oral Anticoagulants; Prevention; Registry; Venous Thromboembolism; Vitamin K antagonists;

D O I：

10.1186/s12959-015-0071-z

中图分类号：

学科分类号：

摘要：

Background: Venous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influencing treatment pathways, patient satisfaction, quality of life (QoL), and utilization of health care resources and the corresponding costs. The PREFER in VTE registry has been designed to address this and to understand medical care and needs as well as potential gaps for improvement. Methods/design: The PREFER in VTE registry was a prospective, observational, multicenter study conducted in seven European countries including Austria, France Germany, Italy, Spain, Switzerland, and the UK to assess the characteristics and the management of patients with VTE, the use of health care resources, and to provide data to estimate the costs for 12 months treatment following a first-time and/or recurrent VTE diagnosed in hospitals or specialized or primary care centers. In addition, existing anticoagulant treatment patterns, patient pathways, clinical outcomes, treatment satisfaction, and health related QoL were documented. The centers were chosen to reflect the care environment in which patients with VTE are managed in each of the participating countries. Patients were eligible to be enrolled into the registry if they were at least 18 years old, had a symptomatic, objectively confirmed first time or recurrent acute VTE defined as either distal or proximal deep vein thrombosis, pulmonary embolism or both. After the baseline visit at the time of the acute VTE event, further follow-up documentations occurred at 1, 3, 6 and 12 months. Follow-up data was collected by either routinely scheduled visits or by telephone calls. Results: Overall, 381 centers participated, which enrolled 3,545 patients during an observational period of 1 year. Conclusion: The PREFER in VTE registry will provide valuable insights into the characteristics of patients with VTE and their acute and mid-term management, as well as into drug utilization and the use of health care resources in acute first-time and/or recurrent VTE across Europe in clinical practice. Trial registration: Registered in DRKS register, ID number: DRKS00004795 © 2015 Agnelli et al.

引用

共 21 条

[1]

Oger E., Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP study group. Groupe d'Etude de la Thrombose de Bretagne Occidentale, Thromb Haemost, 83, 5, pp. 657-660, (2000)

[2]

Cohen A.T., Agnelli G., Anderson F.A., Arcelus J.I., Bergqvist D., Brecht J.G., Et al., Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality, Thromb Haemost, 98, 4, pp. 756-764, (2007)

[3]

Spencer F.A., Emery C., Lessard D., Anderson F., Emani S., Aragam J., Et al., The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism, J Gen Intern Med, 21, 7, pp. 722-727, (2006)

[4]

Martinez C., Cohen A.T., Bamber L., Rietbrock S., Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer, Thromb Haemost, 112, 2, pp. 255-263, (2014)

[5]

Kearon C., Gent M., Hirsh J., Weitz J., Kovacs M.J., Anderson D.R., Et al., A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism, N Engl J Med, 340, 12, pp. 901-907, (1999)

[6]

Konstantinides S.V., Torbicki A., Agnelli G., Danchin N., Fitzmaurice D., Galie N., Et al., 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism, Eur Heart J, 35, 43, pp. 3033-3069, (2014)

[7]

Hutten B.A., Prins M.H., Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism, The Cochrane database of systematic reviews, 1, (2006)

[8]

Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J., Antithrombotic therapy for venous thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines (8th Edition), Chest, 133, 6, pp. 454s-545s, (2008)

[9]

Schulman S., Granqvist S., Holmstrom M., Carlsson A., Lindmarker P., Nicol P., Et al., The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of anticoagulation trial study group, N Engl J Med, 336, 6, pp. 393-398, (1997)

[10]

Ansell J., Hirsh J., Hylek E., Jacobson A., Crowther M., Palareti G., Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th Edition, Chest, 133, 6, (2008)

← 1 2 3 →